We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Flow Cytometry Assay Differentiates Active from Latent Tuberculosis

By LabMedica International staff writers
Posted on 02 Mar 2011
A flow cytometry-based assay identifies parameters of the immune response correlated to protection against tuberculosis (TB). More...


The assay derives functional signatures of immune responses to Mycobacterium tuberculosis (Mtb), the causative organism of TB, such as the cytokines and leucocytes, at different stages of the disease.

The new tool has been developed by scientists at the University of Lausanne, (Lausanne, Switzerland), that distinguishes between active and latent TB. A study recruited 283 participants from a hospital in Switzerland based on positive Mtb-specific interferon gamma (IFN-γ) enzyme-linked immunosorbent spot assay (Becton Dickinson, Allschwil, Switzerland). A validation cohort of 114 participants was obtained from two clinical sites from Switzerland and South Africa. For the flow cytometry analysis cells were stained with antibodies specific for a range of cytokines.

The scientists were able to show that the immune response by the cytokines such as tumor necrosis factor alpha (TNF-α), interleukin 2 (IL-2) and IFN-γ, were correlated to the different stages of tuberculosis disease. The flow cytometry-based assay read-out is focused on the immune response and not on microbiological parameters, thus explaining its reliability and quickness. The sensitivity of the assay was 62% and specificity was 92% for the different stages of TB. The results showed substantial increase in the proportion of single-positive TNF-α Mtb-specific CD4+ T cells, a type of white cell, in subjects with active disease. This parameter was the strongest predictor of diagnosis of active disease versus latent infection.

Giuseppe Pantaleo, MD, professor of medicine and lead author of the study, said, "This assay and the functional signatures of TB-specific immune responses are not only relevant for discriminating between active TB disease and latent infection, but may be also instrumental in monitoring the response to TB therapy." The authors concluded that although the flow cytometry-based assay requires specific equipment and skillful laboratory personnel, further technological development is already under way to make the assay widely accessible. The study was published online on February 20, 2011, in Nature Medicine.

Related Links:
University of Lausanne
Becton Dickinson


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.